NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
2.670
+0.070 (2.69%)
At close: Apr 16, 2026, 4:00 PM EDT
2.660
-0.010 (-0.37%)
After-hours: Apr 16, 2026, 4:48 PM EDT
NovaBridge Biosciences Employees
NovaBridge Biosciences had 30 employees as of December 31, 2025. The number of employees decreased by 2 or -6.25% compared to the previous year.
Employees
30
Change (1Y)
-2
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$2,944,667
Market Cap
308.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 30 | -2 | -6.25% |
| Dec 31, 2024 | 32 | -188 | -85.45% |
| Dec 31, 2023 | 220 | -158 | -41.80% |
| Dec 31, 2021 | 378 | 150 | 65.79% |
| Dec 31, 2020 | 228 | 43 | 23.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Abeona Therapeutics | 226 |
| LENZ Therapeutics | 152 |
| AC Immune | 122 |
| Foghorn Therapeutics | 106 |
| Alector | 103 |
| SAB Biotherapeutics | 86 |
| Inhibikase Therapeutics | 35 |
NBP News
- 9 days ago - NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer - GlobeNewsWire
- 5 weeks ago - Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease - Benzinga
- 5 weeks ago - NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study - GlobeNewsWire
- 6 weeks ago - NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 - GlobeNewsWire
- 6 weeks ago - NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform - GlobeNewsWire
- 2 months ago - NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer - GlobeNewsWire